Head and Neck Mesenchymal Tumors with Kinase Fusions: A Report of 15 Cases With Emphasis on Wide Anatomic

Bin Xu1, Albert J H Suurmeijer2, Narasimhan P Agaram1

  • 1Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Insights

Head and neck mesenchymal tumors with kinase fusions, particularly NTRK gene fusions, are emerging entities. Molecular testing is crucial for diagnosing these rare tumors, especially S100+/CD34+ spindle cell neoplasms.

Area of Science:

  • Oncology
  • Molecular Pathology
  • Genetics

Background:

  • Mesenchymal tumors with kinase fusions are increasingly recognized, primarily in soft tissues.
  • This study focuses on the clinicopathologic and molecular features of head and neck mesenchymal tumors harboring kinase fusions.

Observation:

  • The cohort comprised 15 patients (median age 13 years) with kinase genes including NTRK1, NTRK3, BRAF, MET, and RET.
  • Tumors occurred in diverse head and neck locations and exhibited a wide histologic spectrum, from benign to high-grade.
  • Common features included perivascular hyalinization and staghorn vasculature, particularly in MPNST-like and LPFNT-like tumors.

Findings:

  • NTRK fusions were the most common (NTRK1: 6, NTRK3: 5).
  • Histologic subtypes included MPNST-like, fibrosarcoma, LPFNT-like, and inflammatory myofibroblastic tumor-like.
  • Pan-TRK immunohistochemistry was sensitive for NTRK fusions but negative for other kinase fusions.

Implications:

  • Molecular testing for kinase fusions is recommended for S100+/CD34+ spindle cell neoplasms with specific histologic features.
  • Accurate diagnosis of these rare tumors is essential for appropriate management and understanding their behavior.
  • Identifying kinase fusions aids in targeted therapy selection and predicting patient outcomes.

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.5K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K